Biogen was founded in Geneva in 1978. Today, Biogen is one of the world’s leading biotechnology companies.
One of the pioneers in biotechnology, Biogen today has the leading portfolio of medicines to treat multiple sclerosis (MS) and is at the forefront of research into new medicines for Alzheimer’s disease, other neurodegenerative conditions, and rare genetic disorders. Led by world-class research and development, Biogen advances the latest science and leading-edge technologies to create, commercialize, and manufacture transformative therapies for patients with few or no treatment options.
Our research activities are focused on better understanding the underlying biological mechanisms of disease. This approach enables us to study and market innovative treatments in areas in which there is high unmet need.
Our pipeline contains products for diseases such as Alzheimer’s, MS, spinal muscular atrophy, neuropathic pain syndrome, lupus nephritis and fibrotic illnesses.
The international corporate headquarters of Biogen are in Zug. Biogen currently has more than 400 employees in Switzerland.
The company was rated the third-best employer in Switzerland in the “Great Place to Work 2015” employee survey.
The company is the main sponsor of the Swiss Science Center Technorama in Winterthur and the Children’s University of Zurich.
Biogen Switzerland: www.biogen.ch
The corporate headquarters of Biogen are in Cambridge, Massachusetts, USA, which is also home to our research facilities. Our top-rate production facilities are located in Massachusetts, North Carolina and Luterbach, Switzerland.
The international corporate headquarters of Biogen are in Zug, Switzerland.
Our branches in more than 30 countries and network of distribution partners spanning more than 50 additional countries enable us to offer our therapies to patients around the world.
Biogen is committed to socially responsible corporate citizenship and to conducting its business in accordance with the company’s mission. As part of our commitment, we also provide training and support programs for patients. This allows us to give back to the communities in which we operate, by promoting science education and sustainable activities.
In 2014, the Dow Jones Sustainability World Index named Biogen the leading global biotech company and for the fifth year in a row it was one of just two biotech companies included on the list.
Corporations in the World” list and Newsweek magazine named it the “World’s Most Green Company.”
Biogen has achieved climate neutrality and now has a net zero carbon footprint, which means that it does not produce net emissions of greenhouse gases. We reached this milestone thanks to a multi-year initiative to reduce our emissions. We have also invested in environmental projects in order to compensate for the remaining CO2 emissions that are generated by our business activities, which include the emissions of suppliers as well as those generated by our employees’ business travel.